Zynerba Pharmaceuticals Inc (ZYNE.OQ)
6.28USD
17 Aug 2018
$-0.29 (-4.41%)
$6.57
$6.50
$6.56
$6.26
59,786
99,495
$15.12
$5.59
About
Overall
| Beta: | -- |
| Market Cap(Mil.): | $128.07 |
| Shares Outstanding(Mil.): | 13.26 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ZYNE.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.68 | 32.76 |
| EPS (TTM): | -2.62 | -- | -- |
| ROI: | -55.80 | 1.78 | 14.61 |
| ROE: | -55.80 | 3.28 | 16.33 |
BRIEF-Zynerba Pharmaceuticals Reports Q1 Loss Of $0.91 Per Share
* ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study
* ZYNERBA PHARMACEUTICALS SAYS ZYN002 WAS SHOWN TO BE WELL TOLERATED THROUGH 12 MONTHS OF TREATMENT IN STAR 2
BRIEF-Zynerba Pharmaceuticals Appoints John P. Butler To Board Of Directors
* ZYNERBA PHARMACEUTICALS APPOINTS JOHN P. BUTLER TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)
* ZYNERBA PHARMACEUTICALS INITIATES OPEN-LABEL PHASE 2 TRIAL OF ZYN002 IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEE)
BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60
* ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
BRIEF-Zynerba Pharma Plans To Conduct Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support NDA Filing
* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION AND PLANS TO CONDUCT A SINGLE PIVOTAL STUDY OF ZYN002 IN FRAGILE X SYNDROME TO SUPPORT AN NDA FILING
Competitors
| Price | Chg | |
|---|---|---|
| GW Pharmaceuticals plc (GWP.L) | -- | -- |
| Insys Therapeutics Inc (INSY.OQ) | $7.73 | +0.01 |
| Kalytera Therapeutics Inc (KALY.V) | $0.09 | +0.01 |
| Neuren Pharmaceuticals Ltd (NEU.AX) | $1.30 | -0.01 |
| Marinus Pharmaceuticals Inc (MRNS.OQ) | $5.57 | -0.13 |
Estimates